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a b s t r a c t
Six recombinant vaccinia viruses containing HA, NA, NP, M or NS gene insert derived from a highly
pathogenic avian inﬂuenza H5N1 virus, and the recombinant vaccinia virus harboring plasmid backbone
as the virus control were constructed. The recombinant proteins were characterized for their expression
and subcellular locations in TK cells. Antibodies to the ﬁve recombinant proteins were detected in all 13
sequential serum samples collected from four H5N1 survivors during four years of follow-up; and those
directed to rVac-H5 HA and rVac-NA proteins were found in higher titers than those directed to the
internal proteins as revealed by indirect immunoﬂuorescence assay. Although all 28 non-H5N1 subjects
had no neutralizing antibodies against H5N1 virus, they did have cross-reactive antibodies to those ﬁve
recombinant proteins. A signiﬁcant increase in cross-reactive antibody titer to rVac-H5 HA and rVac-NA
was found in paired blood samples from patients infected with the 2009 pandemic virus.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Based on antigenicity of hemagglutinin (HA) and neuramini-
dase (NA), inﬂuenza A viruses are classiﬁed into 18 HA (H1–H18)
and 11 NA (N1–N11) subtypes, respectively (Forrest and Webster,
2010; Tong et al., 2013; Zhu et al., 2013). All inﬂuenza A viruses
belonging to subtypes H1–H16 are found in aquatic birds, but the
subtypes H17 and H18 were discovered in bats. The inﬂuenza A
subtypes seasonally circulating in human population include the
H3N2 and 2009 pandemic H1N1 (H1N1pdm) viruses (Forrest and
Webster, 2010; World Health Organization (WHO), 2013). Occa-
sionally, certain avian inﬂuenza A viruses have crossed species
barrier to infect humans for example: H5N1, H7N7, H7N2, H7N3
and H9N2 viruses (Centers for Disease Control and Prevention
(CDC), 2013; Forrest and Webster, 2010; Peiris et al., 2007), and a
novel subtype H7N9 found in China in 2013 (Gao et al., 2013). The
highly pathogenic avian inﬂuenza (HPAI) H5N1 virus is the most
virulent avian virus ever reported to infect man.
The genome of inﬂuenza A virus comprises 8 RNA segments
which encode for 10–13 different proteins including 3 polymerase
proteins: polymerase basic protein 2 (PB2), polymerase basic
protein 1 (PB1), and polymerase acid protein (PA), nucleoprotein
(NP), 2 matrix proteins: M1 and M2, and 2 nonstructural proteins:
NS1 and NS2, and 2 surface glycoproteins: HA and NA (Das et al.,
2010). In addition, PB1-F2 and N40 proteins which are translated
from PB1 mRNA, and PA-X which is translated from PA mRNA,
have been discovered in some inﬂuenza subtypes (Jagger et al.,
2012; Wise et al., 2009). It is generalized that HA and NA proteins
are highly variable and immunogenic; while the internal proteins
(PB2, PB1, PA, NP, M and NS) are more conserved across inﬂuenza
subtypes. During inﬂuenza virus infection, antibodies to all major
viral proteins including surface glycoproteins and internal proteins
are produced, indicating that these antigens are exposed to the
humoral immune system (Kreijtz et al., 2011; Lynch et al., 2008;
Sandbulte et al., 2007; Zhang et al., 2011). Antibodies to HA are the
most important for prevention of illness. They can neutralize the
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viral infectivity by interfering with the viral attachment to host
cell receptors, but they are relatively strain speciﬁc because the
epitope responsible for the viral attachment is located on the HA1
variable domain. On the other hand, the antibody to HA2 which is
the conserved domain of HA protein has been shown to exhibit
cross-reactive neutralizing antibody (Sui et al., 2009; Corti et al.,
2010). As the HA2 domain mediates the fusion between the viral
envelope and endosomal membrane during the uncoating step of
the replication cycle, therefore, it is assumed that this broadly
neutralizing antibody inhibits virus uncoating, but not virus
attachment. However, antibodies against the other conserved
proteins also mediated anti-viral activity through various mechan-
isms (Carragher et al., 2008; El Bakkouri et al., 2011; Jegaskanda
et al., 2013; Jegerlehner et al., 2004; LaMere et al., 2011;
Mozdzanowska et al., 1999; Staneková and Varečková, 2010).
As the effectiveness of inﬂuenza vaccine is limited by the emerging
of drifted HA or novel HA subtypes, the development of vaccine
with broader reactivity is crucial. Basically, this type of vaccine
should target the conserved proteins such as those internal
proteins. Nevertheless, the information on magnitude of the anti-
body response to single viral protein is limited owing to lack of the
test antigen. In another word, it is not easy to demonstrate the
subtype-speciﬁc and cross-reactive antibody against individual
inﬂuenza protein of interest without interference from the other
inﬂuenza proteins.
Vaccinia virus has been widely used as a powerful expression
vector for production of antigenically and biologically active
proteins (Hruby, 1990; Mackett and Smith, 1986). Several seasonal
inﬂuenza proteins, including PB2, PB1, PA, HA, NA, NP, M and NS
derived from A/PR/8/34 (H1N1) have been expressed in the
recombinant vaccinia virus infected cells and used to demonstrate
the inﬂuenza subtype-speciﬁc and cross-reactive cellular immu-
nity in mice and humans (Andrew et al., 1986; Jameson et al.,
1998). In the present study, ﬁve recombinant vaccinia viruses
harboring HPAI H5N1 HA, NA, NP, M or NS gene insert were
constructed. The thymidine kinase negative (TK) cells infected
with these viruses were used as the test antigens for detection of
antibodies to recombinant proteins in H5N1 survivors and non-
H5N1 subjects by immunoﬂuorescence (IF) assay. The data on
homosubtypic and heterosubtypic antibodies against an individual
H5N1 protein in our subjects provided a choice of target proteins
for universal vaccine development as well as broaden the under-
standing of inﬂuenza immunity.
Results
Characterization of the H5N1 recombinant proteins
Investigation on the expression and characterization of the
H5N1 recombinant proteins were performed by WB and IF assays.
WB assay demonstrated 3 forms of rVac-H5 HA, the uncleaved
HA0 precursor and its HA1 and HA2 cleavage products whose
molecular weight (MW) were comparable to those of the native
HA proteins synthesized in the MDCK cells infected with A/Thai-
land/1(KAN-1)/2004 (H5N1) (KAN-1 virus), i.e., 75, 55 and 27 kDa,
respectively (Fig. 1, left panel). The rVac-NA, rVac-NP, rVac-M and
rVac-NS proteins had MW of 50, 56, 27 and 26 kDa, respectively;
these were also similar to those synthesized in the KAN-1 virus
infected MDCK cells (Fig. 1, right panel).
Confocal microscopy showed that the rVac-H5 HA and rVac-NA
proteins localized both in the cytoplasm, and in particular, on the
cytoplasmic membrane. The rVac-M protein was mainly found in
the cytoplasm; while the rVac-NP and rVac-NS proteins were
found both in the cytoplasm and nucleus. The TK cells infected
with rVac-pSC11 virus control did not show any ﬂuorescent
positive signal (Fig. 2).
Detection of antibodies against H5N1 viral proteins by IF assay
IF assay was employed for detection of antibodies against rVac-
HA, rVac-NA, rVac-NP, rVac-M and rVac-NS in 13 sequential serum
samples from 4 H5N1 survivors and 38 serum samples from non-
H5N1 subjects (paired blood samples from 5 patients infected with
2009 pandemic A(H1N1) (H1N1pdm) inﬂuenza virus and
5 patients infected with H3N2 inﬂuenza virus and single blood
samples from 18 healthy individuals). In parallel, TK cells
infected with rVac-pSC11 virus were used as the control antigen.
The results demonstrated that all serum samples from H5N1
survivors had antibodies to the 5 H5N1 recombinant proteins
with the titers within the range of 40 to 640; all of these sera had
the antibody titer of 20 against the recombinant control antigen.
Fig. 1. Expression of rVac-H5 HA, rVac-NP, rVac-NA, rVac-M and rVac-NS proteins in TK cells infected with recombinant vaccinia virus as demonstrated by WB assay. The
molecular weight of these recombinant proteins is similar to those native proteins synthesized in MDCK cells infected with KAN-1 virus, but it is higher than those expressed
by the baculovirus-insect cell system (rBV-H5 HA). The HA0, HA1 and HA2 domains at the molecular weight of 75, 55 and 27 kDa are demonstrated in the left panel and the
NP, NA, M1 and NS1 at the molecular weight of 50, 56, 27 and 26 kDa, respectively are demonstrated in the right panel. The asterisk (n) is the recombinant vaccinia virus
expressing NP, NA, M or NS.
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The antibody titers to rVac-H5 HA and rVac-NA proteins were
markedly higher than those to the internal proteins: rVac-NP,
rVac-M and rVac-NS. Additionally, those antibodies could last for
longer than 3 or 4 years as we could follow up that far (Table 1).
The result from paired blood samples of all 5 H1N1pdm patients
showed a signiﬁcant increase in geometric mean titer (GMT) of
Fig. 2. IF assay for expression and localization of H5N1 recombinant proteins in the infected TK cells as visualized under a confocal microscope at objective magniﬁcation of
63 with zoom 2 . TK cells infected with rVac-pSC11 virus is used as the negative control.
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antibodies against the rVac-H5 HA and rVac-NA surface glycopro-
teins, but not to the other recombinant internal proteins (Wil-
coxon Signed Ranks test, po0.05). In contrast, no signiﬁcant
increase in antibody titers against any of the 5 recombinant
proteins was found in paired sera from all 5 H3N2 patients. All
18 healthy subjects also contained the cross-reactive antibodies
against the 5 H5N1 recombinant viral proteins at various titers
(Fig. 3A–E). Additionally, 28 of all 32 subjects contained low
antibody titers (GMT of 13.4) to vaccinia virus when rVac-pSC11
virus infected cells was used as the tested antigen (Fig. 3F).
Detection of neutralizing antibodies against inﬂuenza A viruses
An ELISA-based microneutralization (microNT) assay was
employed for detection of neutralizing antibodies against H1N1,
H3N2 and HPAI H5N1 viruses. All of 4 H5N1 survivors contained
neutralizing antibodies to both the seasonal H1N1 and H3N2
viruses and markedly high antibody titers against H5N1 virus
(Table 1). In contrast, the non-H5N1 subjects had no neutralizing
antibody against H5N1 virus as screen at the serum dilution of
1:10; while they possessed antibodies directed against H1N1 and/
or H3N2 viruses as shown in Table 2.
Conservancy of amino acid sequences among various
inﬂuenza subtypes
Amino acid sequences of KAN-1 virus and human inﬂuenza A
subtypes H1N1, H3N2 and H1N1pdm were retrieved from the
GenBank database and aligned to each other using clustalW
multiple alignment. Accession numbers of these viruses are shown
in the supplementary Table S1. The percentages of amino acid
identity were determined by the sequence identity matrix appli-
cation in BioEdit program version 7.0.4.1, and showed the identity
of more than 90% for PB2, PB1, PA, NP and M1, and 76.5–91.7% for
M2, NS1 and NS2. Much less identity was found in HA and NA
proteins (Table 3).
Discussion
Herein, the recombinant vaccinia virus harboring HA, NA, NP, M
or NS gene insert derived from HPAI H5N1 KAN-1 virus was
constructed; the subcellular location of the expressed proteins
was then demonstrated by IF assay using confocal microscope.
The results were similar to those previous reports such that the
rVac-H5 HA and rVac-NA proteins localized in the cytoplasm and
particular on the cytoplasmic membrane; and the rVac-M, rVac-NP
and rVac-NS proteins were found both in the cytoplasm and
nucleus of the infected cells (Smith et al., 1987). The MW of the
three forms of rVac-H5 HA in this study was similar to those
previously reported in the other studies and our previous lot of
recombinant protein, i.e., 75 or 80 for HA0, 55 or 58 for HA1 and
25 or 27 kDa for HA2 (Noisumdaeng, et al., 2013; Privalsky and
Penhoet, 1978; Skehel and Waterﬁeld, 1975). Our WB assay also
demonstrated the similarity in MW between rVac-NA, rVac-NP,
rVac-M or rVac-NS and those native proteins synthesized in
the KAN-1 virus infected MDCK cells. Collectively, the post-
translational modiﬁcation process such as glycosylation in HA
and NA (Gallagher et al., 1992; Markoff et al., 1984) and phosphor-
ylation in NP, M and NS (Gregoriades et al., 1990; Privalsky and
Penhoet, 1978) in vertebrate cells, i.e., TK cells from human origin
and MDCK from dog origin should be similar. The MW of 50, 56,
27 and 26 corresponding to our rVac-NA, rVac-NP, rVac-M and
rVac-NS, respectively was similar to those reported in the other
studies, i.e., 45 or 58 kDa for NA, 56 or 60 kDa for NP, 26 or 27 kDa
for M1, and 25 kDa for NS1 (Klenk and Rott, 1973; Privalsky and
Penhoet, 1978; Shaw et al., 2008). However, our study did not ﬁnd
the splicing of M mRNAs for M2 protein or NS mRNAs for NS2 pro-
tein, because both M2 and NS2 proteins were not demonstrated by
our WB assay using speciﬁc monoclonal antibody to M2 and NS2
proteins, respectively. The absence of splicing of M and NS mRNAs
in the recombinant vaccinia virus expression system was also
noted by the other investigators (Smith et al., 1987). Therefore, it is
likely that the rVac-M and rVac-NS proteins expressed in our
system might be M1 and NS1 according to their MW and reactivity
with the speciﬁc antibodies to M1 and NS1, respectively.
We employed TK cells infected with recombinant vaccinia virus
as the test antigen to detect homosubtypic and heterosubtypic
Table 1
Homosubtypic antibodies against HPAI H5N1 viral proteins in H5N1 survivors as determined by IF assay.
Survivor no. Age (years) Blood sample Time at blood collection after
disease onset
NT antibody titer to IF antibody titer to
H1N1 H3N2 H5N1 HA NA NP M NS Control antigena
1 32 1 1y 6m ND ND 160 640 320 80 160 160 20
2 2y 6m 640 10 160 640 320 80 80 160 20
3 3y 8m ND ND 80 640 160 160 80 160 20
2 29 1 2y 2m ND ND 160 320 160 80 40 40 20
2 3y 2m 20 80 160 160 320 80 40 160 20
3 4y 3m ND ND 80 320 160 80 40 80 20
3 7 1 20d ND ND 640 320 320 320 80 160 20
2 11m 320 o10 80 320 160 160 80 160 20
3 2y 2m ND ND 80 160 80 160 80 160 20
4 3y 1m ND ND 40 160 80 80 40 160 20
4 2 1 2y 3m ND ND 80 80 80 40 40 40 20
2 3y 11m 160 o10 80 80 160 40 40 80 20
3 4y 11m ND ND 40 80 160 40 40 40 20
y, year; m, month; d, day; NT Ab, neutralizing antibody; IF Ab, immunoﬂuorescence antibody.
ND, not determine.
H1N1: A/Thailand/Siriraj-Rama-TT/2004 (H1N1), an A/New Caledonia/20/1999 (H1N1)-like.
H3N2: A/Siriraj ICRC/SI-154/2008 (H3N2), an A/Brisbane/10/2007 (H3N2)-like virus.
H5N1: A/Thailand/1(KAN-1)/2004 (H5N1) virus.
a Control antigen is prepared from TK- cells infected with rVac-pSC11 virus.
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antibodies to H5N1 HA, NA, NP, M and NS proteins in 4 survivors
of H5N1 infection and 28 non-H5N1 subjects by IF assay. Our
limitation was the number of subjects participated in this study.
There are 25 laboratory conﬁrmed cases of H5N1 infection with 17
deaths in Thailand, and we could enroll only half of the survivors.
Nevertheless, it is laborious and not practical for grading the
antibody titer in large sample size by IF assay. We preliminarily
aimed to demonstrate the existing of cross-reactive immunity to
H5N1 proteins in non-H5N1 subjects; and enrollment of 28 non-
H5N1 subjects revealed presence of such antibodies in all subjects,
and to all kinds of H5N1 proteins. In H5N1 survivors, the antibody
titers to the rVac-H5 HA and rVac-NA were markedly higher than
those to the internal proteins, suggesting that the surface glyco-
proteins HA and NA are more immunogenic. Additionally, those
antibodies could last for 3 to 4 years and could be followed up that
for that long.
The heterosubtypic antibodies against those 5 H5N1 recombi-
nant proteins were demonstrated by IF assay in all 28 non-H5N1
subjects who had no neutralizing antibody to H5N1 virus. A four-
folded rise in antibody titer against HA, NA, or HA and NA or NP
was found in paired sera from all 5 H1N1pdm patients, but with a
signiﬁcant increase of GMT to HA and NA only. In contrast, a
signiﬁcant increase in cross-reactive antibody against any of the
H5N1 viral proteins was not found in the H3N2 patients. These
ﬁndings could be explained such that the HA of H1N1 and H5N1
viruses belonged to the same phylogenetic clade (Medina and
Garcĭa-Sastre, 2011). The H1N1pdm virus and the H5N1 virus were
62% and 84% identical in HA and NA amino acid sequences,
respectively; while the HA and NA of H3N2 virus is quite distinct
from the H5N1 virus by showing only 39% identity in HA and 41%
in NA. Thus, it is postulated that the patients recently infected with
H1N1pdm virus could generate stronger cross-reactive antibodies
Fig. 3. Determination for cross-reactive non-neutralizing antibodies against the recombinant H5N1 viral proteins in non-H5N1 subjects by IF assay: HA (A), NA (B), NP (C),
M (D) and NS (E), and the rVac-pSC11 virus infected TK- cells as control antigen (F). Only H1N1pdm patients show a signiﬁcant increase in GMT against HA and NA proteins in
paired sera (Wilcoxon Signed Ranks test, po0.05).
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against the conserved epitopes in HA and NA than those infected
with H3N2 virus. Using ELISA, previous investigators demon-
strated that individuals infected with seasonal viruses developed
cross-reactive antibodies against HA antigen derived from differ-
ent strains and even different subtypes, i.e., avian H8 HA
(Burlington et al., 1985) and avian H5 HA (Stelzer-Braid et al.,
2008). Our previous work also demonstrated the presence of
antibody to H5 HA2 domain in all non-H5N1 subjects by WB
assay (Noisumdaeng et al., 2013). The H5 HA2 domain has also
been shown by various groups of investigators for its broad
antigenicity and capability to induce cross-reactive neutralizing
antibody (Sui et al., 2009; Corti et al., 2010). Moreover, previous
investigators also reported low neutralizing antibody activities
(Zhang et al., 2011) or cross-reactive binding antibodies against
H5N1 proteins by WB assay in general population (Lynch et al.,
2008). Our previous report also demonstrated cross neutralizing
antibody to H5N1 KAN-1 virus in vaccinees who received seasonal
inﬂuenza vaccine (Kositanont et al., 2010).
It is noted that our H5N1 survivors and non-H5N1 subjects
contained low level of antibody to the control antigen (rVac-pSC11
infected cells) in IF assay. Of all 51 sera including 13 sequential
serum samples from 4 H5N1 survivors and 38 serum samples from
28 non-H5N1 subjects, the GMT of 14.8 were found. Thailand
stopped smallpox vaccination in 1980; therefore, it cannot be
ruled out that the antibody to the control antigen found in the
subjects of age older than 33 years might be due to the long last
persisting anti-vaccinia virus antibody. In particular, the two cases
with the titer of 40 were 43 and 56 years old. At presence, it is still
not known why the non-vaccinia immunized subjects contained
the background of antibody to the control antigen.
The non-neutralizing antibodies might exhibit the important
role in the protection against inﬂuenza virus infection. Antibodies
against HA, NA and M2 facilitated antibody dependent cellular
cytotoxicity which contributed to the clearance of the virus infe-
cted cells (Kreijtz et al., 2011; Jegaskanda et al., 2013; Jegerlehner
et al., 2004; Mozdzanowska et al., 1999). The antibodies to M2e
Table 3
Percentages of amino acid sequence identities among various inﬂuenza subtypes.
Protein Amino acid conservancy rate (% identity)a
Seasonal H1N1 Seasonal H3N2 2009 H1N1pdm
New Caledonia/20 Brisbane/59 Brisbane/10 Wisconsin/67 California/07 Thailand/104
H5N1 (KAN-1) PB2 95.1 94.9 94.4 94.5 97.1 96.8
PB1 95.1 95.3 96.6 96.4 96 95.9
PA 94.2 94.1 93.8 94.1 96.2 96.2
whole HA 62.6 62.1 39.5 38.8 62.2 62.2
HA1 51.1 50.8 33.3 32.7 50 50.2
HA2 80.6 79.7 49.5 48.6 81.5 81
NP 92.3 92.3 90.9 91.5 93.3 93.7
NA 79.7 78.9 41.4 41 84.2 84.2
M1 92.4 93.2 94 94 96 96
M2 81.4 80.4 84.5 84.5 91.7 91.7
NS1 83.4 82.6 79.5 79.5 76.5 76.5
NS2 89.2 88.4 90.9 90.9 87.6 87.6
a Inﬂuenza viruses include A/Thailand/1(KAN-1)/2004 (H5N1), A/New Caledonia/20/1999 (H1N1), A/Brisbrane/59/2007 (H1N1), A/Brisbane/10/2007 (H3N2),
A/Wisconsin/67/2005 (H3N2), A/California/07/2009 (H1N1) and A/Thailand/104/2009 (H1N1). Each protein of all inﬂuenza viruses is aligned and analyzed for the
percentages of amino acid identity by using sequence identity matrix in BioEdit program.
Table 2
NT antibody titers obtained from the 28 non-H5N1 subjects.
Virus subtype Subject group Blood sample Number of cases at NT antibody of GMT
o10 10 20 40 80 160 320 640 41280
H1N1a H1N1pdm patients (n¼5) Acute 1 2 1 1 13.2
Conv. 2 2 1 278.6
H3N2 patients (n¼5) Acute 1 1 2 1 367.6
Conv. 1 1 2 1 367.6
Healthy (n¼18) Single 2 1 3 4 8 718.4
H3N2 H1N1pdm patients (n¼5) Acute 3 1 1 15.2
Conv. 1 2 1 1 26.4
H3N2 patients (n¼5) Acute 3 2 105.6
Conv. 1 2 2 970.1
Healthy (n¼18) Single 1 2 6 5 2 1 1 141.1
H5N1 H1N1pdm patients (n¼5) Acute 4 1 5.7
Conv. 2 3 7.6
H3N2 patients (n¼5) Acute 5 5
Conv. 5 5
Healthy (n¼18) Single 18 5
H3N2: A/Siriraj ICRC/SI-154/2008 (H3N2), an A/Brisbane/10/2007 (H3N2)-like virus.
H5N1: A/Thailand/1(KAN-1)/2004 (H5N1) virus.
Conv., Convalescent.
a H1N1: A/Thailand/Siriraj-Rama-TT/2004 (H1N1), an A/New Caledonia/20/1999 (H1N1)-like virus is used as the test virus in H3N2 patients and healthy individuals;
while A/Thailand/104/2009 (H1N1pdm) virus is used as the test virus in the H1N1pdm patients.
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and NP could eliminate the virus by FcR-mediated phagocytosis (El
Bakkouri et al., 2011; LaMere et al., 2011). Passive transfer of
immune serum obtained from donor mice immunized with the
recombinant NP could promote virus clearance in the recipient
mice after challenging with inﬂuenza H1N1 or H3N2 viruses
(LaMere et al., 2011). Moreover, the anti-NP antibodies could
promote dendritic cell maturation, Th1 cytokine production and,
in addition, stimulate complement-mediated lysis of the inﬂuenza
virus infected P815 cells (Yewdell et al., 1981; Zheng et al., 2007).
Based on these data, it is clear that non-neutralizing antibodies
against internal conserved proteins also confer some degree of
protection.
Our ﬁndings, together with those earlier reports, showed that
the cross-reactive neutralizing and non-neutralizing antibodies
against the conserved epitopes of H5N1 viral proteins exist in
general population, probably as a result of previous infection in
young lives or annual inﬂuenza vaccination. As the antibody
against HA is relatively strain speciﬁc, the effectiveness of annual
vaccine is limited by its inability to induce the antibody that can
neutralize an emerging variant virus. Currently, the inﬂuenza
universal vaccines are targeting on the conserved epitopes of HA
and M proteins based on their functions. The other inﬂuenza viral
proteins such as NA and NP could also confer some effective anti-
inﬂuenza viral activities in vitro and in vivo. However, it is to be
further explored if the antibodies to conserved epitopes in other
inﬂuenza viral proteins as determined by our IF assay could confer
effective anti-viral activities.
Materials and methods
Ethical issues
This study has been approved by two Institutional Review
Boards; the ﬁrst one from the Faculty of Medicine Siriraj Hospital,
Mahidol University, and the second one from the Ministry of
Public Health, Thailand. Subjects signed in the consent form for
participation in this study.
Human subjects and blood specimen collection
The anonymous sera in this study comprised 13 sequentially
archived serum samples from 4 H5N1 survivors, 10 paired sera
collected at approximately 2–3 weeks apart from 5 H1N1pdm
patients and 5 H3N2 patients, and 18 single serum samples from
healthy individuals. Ages of the H5N1 survivors are shown in
Table 1. Mean ages (age-ranges) of the non-H5N1 subjects were as
follows: 21 (21) for H1N1pdm patients; 25 (24–27) for H3N2
patients and 34 (23–56) for healthy subjects. All patients were
diagnosed by real time reverse transcription polymerase chain
reaction (real time RT-PCR), virus isolation and/or serodiagnosis.
Serum samples were kept frozen at 20 1C until used.
The study viruses
Inﬂuenza viruses employed in the present study included HPAI
H5N1 virus, A/Thailand/1(KAN-1)/2004 (H5N1) clade 1 (KAN-1
virus), A/Thailand/Siriraj-Rama-TT/2004 [A/New Caledonia/20/1999
(H1N1)-like virus], A/Thailand/104/2009 (H1N1) virus (H1N1pdm
virus), and A/Siriraj ICRC/SI-154/2008 [A/Brisbane/10/2007 (H3N2)-
like virus]. These viruses were propagated in Madin-Darby canine
kidney (MDCK) cells maintained in Earle's minimal essential medium
(EMEM) (Gibco, Carlsbad, CA) in presence of trypsin-tosyl phenyla-
lanyl chloromethyl ketone (trypsin-TPCK) (Sigma-Aldrich, St. Louis,
MO) and antibiotics, and without fetal bovine serum (FBS) (Gibco)
supplement.
Vaccinia vaccine virus strain Lister, kindly provided by the Thai
Government Pharmaceutical Organization, was used as the par-
ental virus for construction of the recombinant viruses harboring
HPAI H5N1 HA, NA, NP, M or NS gene insert. These vaccinia viruses
were propagated in TK cells maintained in Dulbecco's modiﬁed
eagle medium (DMEM) (Gibco) supplemented with 10% FBS.
The virus stocks were kept at 80 1C until used.
Construction of recombinant vaccinia viruses
The steps of the construction of recombinant vaccinia viruses
involved cloning of H5N1 gene of interest into pGEMs-T Easy
plasmid (Promega Corporation, Madison, WI) and subcloning into
pSC11 vector before transfection into TK cells pre-infected with
the vaccinia virus vaccine strain.
Total RNA was extracted from MDCK cells infected with KAN-1
virus using a QIAamps viral RNA mini kit (Qiagen, GmbH, Hilden,
Germany). The complete genomic segment including HA, NA, NP,
M and NS was ampliﬁed by OneStep RT-PCR kit (Qiagen) using
universal primers (Hoffmann et al., 2001). The HA, NA, NP, M and
NS PCR products at size of 1,807, 1,429, 1,594, 1,056 and 905 base
pairs (bp) in length, respectively were gel electrophoresed and
puriﬁed by using QIAquicks gel extraction kit (Qiagen) and cloned
into pGEMs-T Easy vector by using T4 DNA ligase (Promega)
before transforming into Escherichia coli JM109 cells. The recom-
binant plasmids extracted from the recombinant bacteria were
digested with NotI enzyme to yield the sticky end products that
were further repaired by Klenow DNA polymerase (New England
Biolabs Inc., Ipswich, MA) in order to generate blunt end DNA
strands. The DNA product was subcloned into a pSC11 expression
vector kindly provided by Prof. Bernard Moss, the National
Institute of Allergy and Infectious Disease, Maryland, USA. This
vector contains the SmaI insertion site located downstream of
vaccinia virus p7.5 promoter together with the E. coli lacZ gene
which encodes for β-galactosidase under a p11 promoter, and is
ﬂanked with thymidine kinase sequences (TKR and TKL). E. coli
were transformed with the recombinant plasmids and plated on
Luria-Bertani (LB) agar containing 5-bromo-4-chloro-3-indolyl-β-
D-galactopyranoside (X-gal) (Promega) plus ampicillin as the
selective marker. The cloned bacterial colonies were cultured in
LB broth and the plasmids were extracted by a QIApreps Spin mini
kit (Qiagen). The presence of H5N1 gene insert with correct
orientation was investigated by cutting the puriﬁed recombinant
plasmids by restriction enzymes XhoI/PstI, BamHI/XhoI, PstI/XhoI,
XhoI and HindIII/XhoI (New England Biolabs) for pSC11-H5 HA,
pSC11-NA, pSC11-NP, pSC11-M and pSC11-NS, respectively. DNA
sequencing was performed in order to determine the in-frame
translation of the H5N1 gene insert (Sequencing primers available
on request).
To construct a recombinant vaccinia virus containing H5 HA,
NA, NP, M or NS gene insert (rVac-HA, rVac-NA, rVac-NP, rVac-M
or rVac-NS, respectively), a mixture of pSC11 recombinant plasmid
together with DMRIE-C transfection reagent (Invitrogen, Carlsbad,
CA) in DMEM was inoculated onto the TK cell monolayer that
were pre-infected with parental vaccinia vaccine virus at the
multiplicity of infection (MOI) of 0.01 plaque forming unit
(PFU)/ml for 2 h. The H5N1 DNA ﬂanked with TKR and TKL was
inserted into the parental vaccinia viral genome by homologous
recombination with the tk gene. The transfected culture was
further incubated for 2 days to allow virus replication. As a result,
the recombinant virus harboring the H5N1 gene insert gains the
TK phenotype, which results in the loss of the ability to produce
thymidine kinase enzyme. The recombinant vaccinia virus was
distinguished from the parental TKþ vaccinia virus by plaque
selection on the TK cell monolayer maintained in low melting
point agarose containing 5-bromo-2'-deoxyuridine (BrdU) (Sigma
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Aldrich, St. Loius, MO) and X-gal, in which the plaques produced
by cells infected with the recombinant vaccinia virus appeared
blue. Plaque puriﬁcation was performed three times in order to
obtain the single clone of the recombinant virus. In parallel, the
recombinant vaccinia virus containing pSC11 vector (rVac-pSC11)
was constructed for using as the vaccinia virus control. The
recombinant vaccinia virus was propagated and titrated in TK
cells by plaque assay, and further characterized by WB and IF
assays.
Preparation of H5N1 viral antigens
TK cells infected with the recombinant vaccinia virus harbor-
ing H5N1 HA, NA, NP, M or NS gene insert were used as the
antigens in IF and WB assays. Additionally, MDCK cells infected
with KAN-1 virus was used as the positive control antigen. For WB
assay, the infected cell pellets were re-suspended with RIPA buffer
(50 mM Tris Cl pH 7.5, 150 mM NaCl, 1% Tritons X-100, 0.5%
sodium deoxycholate, 0.1% SDS) to yield the cell lysates containing
the test antigens. For IF assay, the infected cell suspensions were
deposited on microscopic glass slides, air dried and ﬁxed with pre-
cooled acetone at 20 1C for 10 min. The ﬁxed slides were kept at
80 1C until stained.
Western blot assay
HA, NA, NP, M and NS proteins expressed in TK cells infected
with the recombinant vaccinia virus were characterized in com-
parison with the native H5N1 viral proteins produced in MDCK
cells infected with H5N1 KAN-1 virus by WB assay. Brieﬂy, the
infected cell lysates or recombinant antigens were mixed with 4X
reducing sample buffer (8% SDS, 250 mM Tris Cl pH 6.8, 8%
β-mercaptoethanol, 0.4% bromophenol blue, 40% glycerol), boiled
at 95 1C for 5 min and subjected to 10% SDS-PAGE. The proteins in
gel were blotted onto a nitrocellulose membrane (Protrans,
Whatman, GmbH, Germany) by using Trans-Blots SD semidry
transfer cell (Bio-Rad). The blotted membrane was blocked with
5% skim milk in Tris-buffer saline plus 0.1% tween-20 (TBS-T). MW
of the native and recombinant H5N1 viral proteins was deter-
mined using the speciﬁc primary antibodies as follows: goat
antiserum against A/Vietnam/1203/2004 (H5N1) (VN1203) HA
kindly provided by Prof. Robert G. Webster and Dr. Richard Webby,
St. Jude Children's Research Hospital, TN; mouse monoclonal
antibody to VN1203 HA as well as rabbit polyclonal antibody
against synthetic peptide corresponding to 15 amino acids at
the carboxy terminus of NA from avian inﬂuenza H5N1 virus (US
Biological, Swampscott, MA); goat antibody to M protein (US
Biological, Swampscott, MA); mouse monoclonal antibody to NP
(Millipore Corporation, Temecula, CA); and goat anti-NS1 poly-
clonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA).
The anti-species speciﬁc immunoglobulin comprising horseradish
peroxidase (HRP) enzyme conjugated rabbit anti-goat Igs (Dako
Cytomation, Glostrup, Denmark), goat anti-rabbit Igs (Zymed
Laboratories, San Francisco, CA) or goat anti-mouse Igs (Dako)
was used as the secondary antibody. The blotted membrane was
incubated with the primary antibody overnight at 41C before
washing with TBS-T and followed by incubation with the corre-
sponding secondary antibody for 2 h at room temperature. The
mixture of 3,3'-diaminobenzidine (Sigma-Aldrich, St. Louis, MO),
8% NiCl2 and 6% H2O2 was used as the chromogenic substrate.
Immunoﬂuorescence assay
IF assay was performed for 2 purposes in this study. The ﬁrst
one was to investigate for the expression and localization of the
H5N1 recombinant proteins expressed in TK cells. The second
purpose was to determine the antibody titers against H5N1
proteins in human sera. Cell deposits were incubated with primary
speciﬁc antibodies for 1 h at 37 1C, and then followed by the
secondary antibodies: ﬂuorescein isothiocyanate (FITC) conjugated
rabbit anti-goat Igs (Dako Cytomation), goat anti-rabbit Igs
(Abcam, plc., Cambridge, UK), goat anti-mouse Igs (Light Diagnos-
tics™, Temecula, CA) or goat anti-human IgG (Invitrogen, Frederick,
MD) for 1 h at 37 1C and counter stained with 0.5% Evan's blue dye.
The stained slides were examined under an ordinary ﬂuorescence
microscope (Nikon Eclipse 80i, Japan) by two independent scien-
tists in order to avoid bias in grading the antibody titer. The
reciprocal of the last serum dilution which yielded the ﬂuores-
cence intensity of 2þ was considered to be the antibody titer.
On the other hand, the stained slides for confocal microscopy were
counter stained with trihydrochloride trihydrate (Hoechst 33342-
Invitrogen, Eugene, Oregon) for nuclear staining together with
0.5% Evan's blue dye for 10 min. The slides were examined for
ﬂuorescent cells under a laser scanning confocal microscope (LSM
510 Meta, Zeiss, Jena, Germany).
Microneutralization assay
ELISA-based microNT assay was carried out in duplicate in
MDCK cell monolayers. The protocol was conducted according to
that described previously (Lerdsamran et al., 2011). Brieﬂy, the test
serum was treated with receptor destroying enzyme (RDE) (Denka
Seiken, Tokyo, Japan) and followed by heat inactivation at 56 1C for
30 min. The treated serum was serially 2 fold-diluted before
adding with the test virus at ﬁnal concentration of 100 TCID50/
reaction in duplicate. Amount of viral nucleoprotein in the reaction
wells was determined by ELISA using mouse-speciﬁc anti-NP
monoclonal antibody (Chemicon, Temecula, CA) as the primary
antibody, and HRP conjugated goat anti-mouse Igs (Southern
Biotechnology, Birmingham, AL) as the secondary antibody, and
TMB (KPL Inc., Gaithersburg, MD) as the chromogenic substrate.
The neutralizing (NT) antibody titer was deﬁned as the reciprocal
of the highest serum dilution that reduces Z50% of the amount of
viral nucleoprotein in the reaction wells as compared to the virus
control wells. The geometric mean titer (GMT) was calculated by
assigning the antibody titer o10 as 5.
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